India, July 2 -- Nektar Therapeutics (NKTR), a clinical-stage biotech firm specializing in immunotherapy, has priced its underwritten public offering of approximately $100 million in common stock.
The company will issue 4,255,320 shares at $23.50 per share, with gross proceeds expected to be around $100 million before underwriting discounts and offering expenses.
Additionally, underwriters have a 30-day option to purchase up to 638,298 more shares at the same price, excluding underwriting fees. The offering, which includes only Nektar-issued securities, is expected to close on July 2, 2025, subject to customary conditions.
Proceeds from the offering will be used for general corporate purposes, including R&D, clinical development, and man...